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Abstract: Landmark trials in 2002 showed that therapeutic hypothermia (TH) after out-of-
hospital cardiac arrest due to ventricular tachycardia or ventricular fibrillation resulted in 
improved likelihood of good neurologic recovery compared to standard care without TH. 
Since that time, TH has been frequently instituted in a wide range of cardiac arrest patients 
regardless of initial heart rhythm. Recent evidence has evaluated how, when, and to what degree 
TH should be instituted in cardiac arrest victims. We outline early evidence, as well as recent 
trials, regarding the use of TH or targeted temperature management in these patients. We also 
provide evidence-based suggestions for the institution of targeted temperature management/
TH in a variety of emergency medicine settings.
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Introduction
Cardiac arrest is common, occurring in more than 320,000 nonhospitalized people 
yearly in the USA alone.1 Of those treated by emergency medical services personnel, 
approximately 23% present with a shockable initial heart rhythm (ventricular 
tachycardia or ventricular fibrillation [VF]).1 Despite ongoing efforts to improve resus-
citative and postresuscitative care, cardiac arrest still carries a dismal prognosis, with 
survival to hospital discharge occurring in 7%–11% of patients with out-of-hospital 
cardiac arrest (OHCA)1,2 and 25% of patients who arrest in hospital.1 Historically, once 
return of spontaneous circulation (ROSC) is achieved, there is little evidence to support 
any particular therapy or intervention. In 2002, two landmark studies3,4 reported that 
cooling the bodies of postarrest patients who had an initially shockable heart rhythm 
to 32°C–34°C for a period of time after ROSC resulted in a greater likelihood of 
neurologically intact survival. This therapeutic hypothermia (TH) has since become 
standard care for patients with ROSC after cardiac arrest. Despite a lack of high-level 
evidence in cardiac arrest patients with nonshockable initial rhythms or in-hospital 
arrest, TH is now commonly applied to any patient with ROSC after cardiac arrest, 
whether in hospital or OHCA, and any presenting rhythm.5–7
Recently, two large randomized trials8,9 introduced considerable controversy to the 
discussion about how, when, and to what degree we should be instituting temperature 
control in postarrest patients. The objective of this review is to give an overview of 
the evidence surrounding TH in patients with ROSC after cardiac arrest, and provide 
evidence-based suggestions for temperature management of cardiac arrest victims in 
a variety of emergency-medicine settings. When possible, we focus on evidence from 
randomized trials. We try to address specifically when, how, and to what temperature 
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we should be managing the temperature of postarrest patients. 
Lastly, we present a structure for instituting temperature 
control and outline some pearls and pitfalls in doing so. We 
use the term “targeted temperature management” (TTM) to 
refer to strict temperature control at any temperature. TH 
will be used to refer to temperature control targeting body 
temperatures of 32°C–34°C.
Background and pathophysiology
TTM is a form of treatment aimed at achieving and main-
taining a specific core body temperature for a duration of 
time to improve outcomes.10 This is done in an attempt to 
reduce the risk of tissue injury from the lack of blood flow 
that can be seen as a result of cardiac arrest. TTM is thought 
to limit brain injury by decreasing cellular metabolism and 
the brain’s oxygen demand by reducing the production of 
excitatory neurotransmitters like glutamate, minimizing the 
disruption of ion homeostasis, and by reducing free radicals 
that might further injure at-risk neurons.11–13 Most centers 
now either actively cool or control temperature by using TH 
or temperature-management protocol (example in Figure 1) 
for 24 hours to a goal cooling temperature of 32°C–34°C 
Return of spontaneous circulation (ROSC)  
Airway and breathing 
• Maintain and protect airway 
• Administer O2 to maintain SpO2 94%–98% 
• Do not hyperventilate 
• Maintain respiratory rate of 10–12/minute 
• Monitor ETCO2/SpO2; target pCO2 35–45 mmHg 
Circulation 
• Treat hypotension (SBP <90 mmHg) 
• Consider fluid bolus 
• Consider norepinephrine; begin at 0.01 µg/kg/min, titrate to an MAP goal
of greater than 80 mmHg   
• Obtain a 12-lead EKG 
• Treat STEMI cases per protocol, consider PCI-capable facilities 
Evaluate inclusion and exclusion criteria for TTM 
• Cardiac arrest from suspected medical etiology
and the patient is unresponsive
(GCS <8) and hemodynamically stable
Initiate targeted temperature management 
• Apply ice packs to axilla/chest/groin 
• Administer cold IV fluids 30 mL/kg at 500 cc increments 
• Monitor temperature 
• Treat shivering 
• Prepare for continuous cooling 
• Notify inpatient unit or consider transfer to TTM-capable facilities 
Figure 1 Targeted temperature management (TTM).
Abbreviations: SpO2, peripheral capillary oxygen saturation; ETCO2, end-tidal carbon dioxide; pCO2, partial pressure of carbon dioxide; SBP, systolic blood pressure; MAP, mean 
arterial pressure; EKG, electrocardiogram; STEMi, ST-elevation myocardial infarction; PCi, percutaneous coronary intervention; GCS, Glasgow Coma Score; iv, intravenous.
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or maintain normothermia at 36°C.14–16 Standard protocols 
aim for initiating temperature control within the 1st hours 
of collapse (0–6 hours) to achieve the target temperature 
as quickly as possible (within 8 hours of cooling initia-
tion).14,16,17 Rewarming is typically begun 24 hours after the 
initiation of cooling for patients cooled to a 32°C–34°C 
target, and is done slowly (0.1°C–0.5°C per hour) until 
36°C is reached. In some centers, temperature management 
is maintained at 36°C for the next 48 hours independently 
of initial target temperature. Likewise, centers that use 36°C 
as a temperature-management target typically control body 
temperature at this target for 72 hours.
A basic understanding of some landmark trials in TH is 
necessary in order to try to answer some of the  questions we 
address in this article. TH after cardiac arrest was brought 
to the forefront in 2002 by two trials published in the New 
 England Journal of Medicine. Bernard et al3 enrolled 
77 patients with ROSC after OHCA and an initial cardiac 
rhythm of VF in a quasi-randomized fashion. Patients 
assigned to TH had cold packs and ice packs applied to 
their head, neck, and torsos until they were 33°C. This tem-
perature was maintained for at least 12 hours. Patients were 
then rewarmed with heating blankets to normothermia by 
24 hours after hospital admission. Twenty-one of 43 patients 
(49%) assigned to hypothermia were released from the 
hospital with “good neurologic outcome”. This end point 
was achieved in only nine of 34 patients (26%) assigned to 
no temperature control, which was a statistically significant 
difference.
At the same time, a second trial was published by the 
Hypothermia After Cardiac Arrest (HACA) study group.4 
This larger randomized trial similarly enrolled postarrest 
patients who had an initial rhythm that was shockable (ven-
tricular tachycardia or VF). Of approximately 3,500 patients 
screened, the trial ultimately enrolled 275 patients. Those 
 randomized to TH were cooled to a target of 32°C–34°C 
using cooling blankets that circulated cold air, with ice 
bags used additionally if necessary. This temperature was 
maintained for approximately 24 hours, followed by pas-
sive rewarming. This trial found that 75 of 136 patients 
(55%) randomized to TH had a “favorable neurologic out-
come” compared to 54 of 137 (39%) of the normothermic 
patients. Again, this difference in outcomes was statistically 
significant.
The methods and duration of cooling in these trials were, 
as just outlined, heterogeneous, but the results were consis-
tent and suggested a large increase in neurologically intact 
survival with TH employed by relatively simple methods. 
While these two trials have formed the backbone of support 
for TH after cardiac arrest, several observational studies5,7,18,19 
have been published since then, mostly reporting similar 
benefits associated with TH. In 2002, the International Liaison 
Committee on Resuscitation began recommending TH be 
instituted in all patients with ROSC after an initially shockable 
rhythm and considered in those with nonshockable rhythms.20 
These guidelines have not changed significantly since then.
In 2013, Nielsen et al published a much larger randomized 
trial that compared controlled normothermia at 36°C to 
controlled hypothermia at 33°C.9 This trial enrolled patients 
with any initial rhythm, and patients were cooled with more 
sophisticated equipment, which allowed more tightly controlled 
body temperatures. In this trial of over 950 patients, the two 
temperature targets were equivalent in terms of survival and 
neurologically intact recovery. Among the patients cooled to 
33°C, mortality was 50% at the end of the trial, and 54% had 
either died or had poor neurologic function at 180 days. Of 
the patients maintained at 36°C, the corresponding numbers 
were 48% mortality and 52% with poor neurologic outcome 
or death. Results were similar for patients with shockable or 
nonshockable rhythms. There was no statistical difference in 
outcomes, and the authors concluded that TH at 33°C conferred 
no benefit over TTM at 36°C.
At nearly the same time, Kim et al published a negative 
trial of prehospital TH.8 This trial randomized 1,369 patients 
with OHCA to either immediate cooling by prehospital 
providers with cold saline (4°C) or standard prehospital 
management without cooling. By protocol, the patients 
who survived to hospital admission were to undergo TH in 
the hospital. Survival was 37.6% in patients cooled in the 
field versus 37.1% in controls. Good neurologic recovery 
was 32.7% in cooled patients versus 34.4% in controls. 
Results were similar for patients with initial shockable and 
nonshockable rhythms, though in-hospital TH was inconsis-
tently applied to patients with nonshockable rhythms.
An understanding of these few trials is imperative for 
any informed discussion regarding the finer points of when 
and how to institute TTM after cardiac arrest. These trials 
are referenced throughout the rest of this review.
What is the optimal temperature 
target?
Prior to Nielsen et al’s study,9 data from randomized  trials were 
limited to demonstrating that 32°C–34°C for 12–24 hours was 
superior to no temperature control. There was very limited 
evidence to guide further what exact temperature would be 
most beneficial. Further, this benefit was only proven in 
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patients with shockable rhythms on presentation. Nielsen 
et al’s study showed that strict temperature management to 
maintain normothermia at 36°C resulted in similar outcomes 
to hypothermia at 33°C. The study included patients with 
any presenting rhythm. The authors postulated that fever 
avoidance was the key, as opposed to actual cooling to a 
hypothermic temperature. Nielsen et al did find that electrolyte 
abnormalities were slightly more common in patients cooled 
to 33°C, which is of unclear clinical meaning. In a secondary 
analysis, the authors also found that vasopressor requirements 
were higher in the hypothermic group compared to patients 
maintained at normothermia.21 It thus may be that a target of 
36°C is associated with moderately fewer side effects than 
a hypothermic protocol, but these small differences did not 
result in a difference in patient-important outcomes. There 
are no convincing data to suggest that one temperature target 
is superior to another.
A recent trial22 representing the first randomized trial of 
TH versus normothermia in children found that temperature 
management at a goal of 36.8°C was as effective as target-
ing 33°C. Enrollees had their target temperature maintained 
for the first 48 hours, then were brought to a target of 36.8°C 
through a total of 120 hours of temperature control. The trial 
enrolled 260 patients with full outcome data, and found that 
survival with good neurologic recovery was 20% in the 
hypothermia group and 12% in the normothermia group 
(P=0.14). Secondary outcomes were similarly distributed 
and not statistically different between the groups.
Given the results of these randomized studies and lack 
of meaningful benefit or harm associated with hypothermia 
versus controlled normothermia, either temperature goal 
seems reasonable. Practice patterns may eventually be 
decided by which temperature target is easier to maintain. 
If a simple and inexpensive method for maintaining 
temperature at 36°C is validated, decreasing costs compared 
to  hypothermia, this might make a stronger argument for 
normothermia. It should be pointed out, however, that both of 
these trials comparing TTM at different temperatures9,22 used 
advanced temperature-control devices in all of the enrolled 
patients. While these devices have not proven superior to 
easy, inexpensive methods (ice packs and cold saline) for 
patients receiving TH,23 their efficacy compared to simple 
methods has not been studied in controlled normothermia.
Special considerations for choosing 
a temperature target
Adverse events and possible complications of hypothermia 
may include bleeding, dysrhythmias,  electrolyte abnormalities, 
hyperglycemia, infection, and skin breakdown.11,12,24–26 Though 
fatal arrhythmia produced by hypothermia is seemingly rare, 
sinus tachycardia is commonly seen at the time of hypothermia 
induction, and when body temperature falls below 35.5°C, 
a sinus bradycardia occurs.27,28 Typical electrocardiogram 
changes seen during hypothermia include an increase in the 
intervals between different waves (P–R, Q–T), the widening 
of the wave of ventricular depolarization (QRS), and occa-
sionally a prominent J-point deflection or Osborne wave.28 
Serum electrolyte disturbances occur as a result of increased 
renal excretion of electrolytes, due to changes in circulating 
blood volume, cardiac preload, and impaired tubular function 
and as a result of intracellular shift during hypothermia.27,28 
The most common electrolyte disturbances seen are mag-
nesium deficiency and hypokalemia, though hypocalcemia, 
hyponatremia, and hypophosphatemia also occur with some 
frequency.28 Though many of these disturbances can be tran-
sient, preventing severe electrolyte imbalance caused by hypo-
thermia should be the main target of electrolyte treatment.27,28 
Infection, historically the most feared risk of prolonged TH, 
might have no greater prevalence in this population than that of 
matched critically ill patients.24 Similarly, recent investigators 
found that hypothermia was associated with a small but not 
statistically significant trend toward increased bleeding, and 
found no associated increase in severe bleeding.26 Invasive 
lines, especially cooling catheters, can predispose resuscitated 
patients to inadvertent vascular puncture, bleeding, infection, 
and deep-vein thrombosis, so extreme care must be taken 
during placement and maintenance.25,27
In summary, there is little evidence to suggest that 
meaningful complications are more common with TH than 
with controlled normothermia in any particular subgroup 
of patients. However, normothermia may be preferred in 
patients thought to be at particularly high risk for complica-
tions associated with hypothermia, such as severe preexist-
ing electrolyte abnormalities, hemodynamic instability, 
infection, or bleeding disorders. Some of these are examples 
of conditions that have traditionally been considered con-
traindications to TH (Table 1), but may be appropriate for 
controlled normothermia.
When should TTM be initiated?
For the past decade since TH has been introduced into pos-
tarrest care, recommendations have been to start cooling 
patients as soon as possible after or even before ROSC. In 
referral centers with experience in postarrest care, the answer 
is relatively simple: patients should have TTM instituted as 
soon as they are stabilized. The question is more difficult for 
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physicians working in locations where postarrest patients 
will be routinely transferred to a referral center. Directors of 
prehospital services (emergency medical services) have also 
struggled with whether or not early initiation of TH in the 
field immediately after (or even prior to) ROSC would add 
benefit. Common sense would dictate that if TH or tempera-
ture control is beneficial, then earlier institution of it should 
improve its efficacy, and thus patient outcomes. However, 
evidence to support this has not been borne out.
There are conflicting results from comparative observation 
studies in humans undergoing TH. A small trial (n=49) 
in 2009 by Wolff et al29 found an independent association 
between shorter time to coldest temperature and cerebral 
performance-category score #2 (representing a favorable 
outcome), although there was no association with either time 
to TH initiation or time to target temperature. That same year, 
Nielsen et al30 reported on a much larger cohort (n=986), and 
found no association between time to initiation or time to 
target temperature and patient outcomes. In 2011, Mooney 
et al reported a 20% increase in mortality for every hour’s 
delay in TH initiation among 140 patients.7 The ICE study 
group, however, found a significant independent association 
between early initiation of TH and increased mortality in 
their cohort of 121 Italian patients.31 Similarly, Haugk et al 
found improved survival (adjusted odds ratio of 1.86) among 
588 patients to be independently associated with longer time 
to target temperature.32 While the results of these studies 
showed only associations and not causality, there is no con-
vincing evidence that very early TH offers additive benefit 
over slightly delayed TH. It is also noteworthy that the median 
time to target temperature for patients randomized to TH in 
the HACA trial33 was relatively long, at 8 hours.
Perhaps more convincing data are now available from 
randomized trials regarding prehospital initiation of TH. 
Prior to 2013, six randomized trials18,34–38 of very early 
prehospital  initiation of TH had been performed. While 
patients  randomized to prehospital cooling generally reached 
target temperature faster, none of the trials found any patient-
 important benefit. Two meta-analyses39,40 of these trials 
 published in 2013 and 2014 found no evidence of any clini-
cally  important benefit with prehospital TH. Then, Kim et al 
 published their trial of 1,369 patients,8 nearly solidifying that 
prehospital TH offered no advantage over waiting to initiate 
TH until after hospital arrival. Kim et al’s trial did show that 
early rearrest and pulmonary edema were more common 
with  prehospital cooling, suggesting that rapid  infusion of 
cold saline for immediate cooling may be  associated with 
significant harms, though ultimately survival and neurologic 
recovery were similar between groups. It should be noted 
that approximately 50% of the patients admitted after being 
resuscitated from a nonshockable rhythm in Kim et al’s trial 
did not actually receive in-hospital cooling, decreasing the 
certainty that the intervention would not have been useful 
had these patients undergone continued cooling after hospital 
arrival. Despite this uncertainty in patients with nonshock-
able rhythms, the bulk of the evidence is clearly in favor of 
no benefit with very early initiation of TH.
These results are perhaps not surprising in light of 
the evidence that now suggests that patients need not be 
actually cooled, as opposed to maintained at normothermic 
temperatures. Postarrest patients are generally below nor-
mothermic levels at hospital arrival.8,34,35,38 This means that 
as long as one believes that 36°C is an appropriate target 
temperature, they are already at target. Therefore, earlier 
initiation of “cooling” theoretically offers no benefit, as the 
temperature is already “controlled”, until it goes outside the 
range that is maintained while targeting 36°C.
Since the safety of uncontrolled temperatures above 
those obtained while targeting 36°C (36.8°C in  children) 
is unproven, and perhaps doubtful, we suggest that 
TTM be mandatorily instituted before a patient becomes 
hyperthermic, but that as long as hyperthermia is avoided, 
the timing of initiation is otherwise likely to be of little 
relevance. This requires early institution of continuous 
temperature monitoring in all postarrest patients. Given that 
among those randomized to normothermia in Nielsen et al’s 
Table 1 Targeted temperature management: exclusion criteria 
and contraindications to active cooling to a 32°C–34°C target
Exclusion criteria
Purposeful response to verbal commands or noxious stimuli after ROSC 
and prior to initiation of hypothermia
Recurrent vF or refractory vT in spite of appropriate therapy
Absolute contraindications
Hemorrhagic stroke
Cardiac arrest due to trauma
GCS .8
Uncontrolled, active bleeding
Uncontrolled hemodynamically unstable rhythms
Relative contraindications
Prolonged cardiac arrest (.60 minutes)
Refractory hypotension despite fluid and vasopressor support – consider 
ECMO
Thrombocytopenia (PLTs ,50K) or baseline coagulopathy
Note: Many of the contraindications mentioned in the table might not limit 
application of targeted temperature management, and institutional consensus should 
be followed on a case-by-case basis.
Abbreviations: ROSC, return of spontaneous circulation; VF, ventricular fibrillation; 
vT, ventricular tachycardia; GCS, Glasgow Coma Scale; ECMO, extracorporeal 
membrane oxygenation; PLTs, platelets.
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study, the 95% interval around the average temperature 
was above 37.0°C for all time points,9 we recommend 
initiating aggressive temperature control measures before 
the (invasively measured) body temperature reaches 36.5°C. 
In settings where advanced techniques are not readily or 
quickly available, the aggressive application of ice packs to 
the body with or without infusion of cold intravenous fluids 
prior to a temperature of 36.5°C should be sufficient to avoid 
any significant chance of hyperthermia.
What methods should be employed 
to institute TTM?
The landmark trials of TH in 2002,3,33 as outlined earlier, used 
crude methods for cooling compared to today’s technologies. 
The main tools employed were ice packs and cold-air cooling 
blankets, and it took 8 hours on average to achieve TH in the 
HACA trial.33 It was these methods for cooling that initially 
appeared so effective in improving postarrest outcomes. Since 
that time, methods to cool patients more efficiently have been 
aggressively pursued. Randomized studies have sought to 
define ways to cool patients faster, keep temperatures closer to 
target, or make temperature control easier.23,41 Some methods 
have proven useful for these goals, but the hopes that these 
more efficient methods of cooling would provide improved 
patient outcomes have not come to fruition.
The Arctic Sun® system is a well-studied method for 
external cooling that uses external cooling pads placed on 
various parts of the patient’s body. This device mechanically 
circulates temperature-controlled water through dermally 
applied gel pads. In an often-cited study comparing Arctic Sun 
to cooling blankets and ice packs, patients randomized to Arctic 
Sun achieved target temperature more quickly (by 54 minutes 
on average), but good neurologic recovery was unaffected.23
Invasive means of cooling patients appear to be even more 
effective in terms of fast and controlled temperature control. 
Pittl et al41 studied the invasive CoolGuard® system against 
Arctic Sun in 80 postarrest patients. They found that the 
invasive system maintained more stable temperature control, 
but did not affect clinical outcomes or neuron-specific enolase 
levels, which the authors measured as a surrogate marker for 
brain damage. Bleeding complications were significantly 
more common in the CoolGuard group.
Pearls and pitfalls in the first 12 
hours of TTM
Patients undergoing TTM after cardiac arrest are typically 
critically ill, and we recommend both central venous and 
arterial access within the early hours of care. When cooling 
to 32°C–34°C, early access can be critical, since the effects of 
peripheral vasoconstriction at a cooler goal temperature can 
make obtaining access markedly more difficult. The control 
of body temperature may be accomplished by many means, 
including the use of dermally applied gel and water-cooled 
pad devices, cooling blankets, cooling helmets, cooling 
catheters, ice packs, cooled fluid bolus, endovascular cooling 
devices, and ice-water lavage, though as outlined earlier it is 
unclear if any one method is superior to the others.42
Continuous core body temperature should be monitored 
to provide data to modulate cooling efforts and to avoid 
overcooling. Temperatures below 30°C (86°F) should 
be avoided, as adverse events, especially life threatening 
arrhythmia and bleeding, increase significantly below 30°C.42 
Esophageal, rectal, and bladder probes have been commonly 
used to monitor core temperature, though data suggest that 
rectal temperatures can be unreliable.43 Invasive lines, such 
as a pulmonary artery temperature probe, can be used if 
available, and several endovascular and gel heat-transfer 
cooling systems integrate a temperature probe that is used 
to modulate cooling system output.
Sedation and shivering control
Patient comfort and sedation should be assessed and institu-
tional guidelines followed regarding patient monitoring and 
the treatment of pain and agitation. Pain can be controlled 
with common narcotic analgesics, such as morphine or 
 fentanyl, and sedation can be maintained with such agents 
as lorazepam, midazolam, or propofol (Table 2).
Shivering, the body’s attempt to maintain temperature 
homeostasis, can contribute to discomfort and interfere with a 
controlled thermic state, so prior to the induction of tempera-
ture management, pharmacological agents to control shivering 
should be administered.10,42,44–46 Shivering typically begins 
when a body temperature drops below a certain threshold, 
typically approximately 36°C, and often appears regardless 
of the technique used to induce hypothermia.44,45 It is unclear 
whether different temperature targets result in significant 
differences in the amount of shivering, and we believe that 
a similar approach and algorithm for shivering control is 
reasonable, regardless of the temperature target chosen.
In some cases, shivering will be controlled with routine 
sedative drips alone (fentanyl, propofol, benzodiazepines). 
When these standard measures fail, the drugs most commonly 
employed to prevent shivering in TTM are acetaminophen, 
buspirone, desflurane, dexmedetomidine, and meperidine.46–48 
Common sedatives used during TH to reduce the shivering 
threshold include propofol, dexmedetomidine, midazolam, 
and diazepam. Though fentanyl and morphine are the more 
commonly used opiates during TTM therapy,49 meperidine 
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has been the most efficacious of the opiates with regard to 
shiver management, with recorded reductions in the shivering 
threshold of 1.2°C–6.1°C to a level 33°C.47,49–52 Buspirone, 
a serotonin 1A partial agonist, and meperidine appear to lower 
the shivering threshold in synergism, achieving even lower 
shivering thresholds.53 Magnesium sulfate has been studied 
as a bolus with infusion as a means to improve targeted 
cooling times54 and perhaps enhance shivering thresholds in 
combination with other agents.48,55
Nonpharmacologic means of shiver reduction largely focus 
on skin counterwarming (total-body forced-air rewarming, 
focal hand rewarming, and focal face/head rewarming) as a 
means to reduce shivering and vasoconstrictive thresholds.48,56,57 
Evidence supports a 1°C decrease in shivering threshold for 
every 4°C increase in skin temperature.56 Endovascular cooling 
may allow better access to the skin to employ counterwarming 
compared to external cooling measures that require the skin 
to be cooled directly. When shivering occurs despite optimal 
pharmacologic and nonpharmacologic means, protocols 
often include the use of a paralytic agent (ie, neuromuscular 
blocker) to control shivering. Because of the challenges of 
monitoring sedation, neurological examination, and seizures 
when paralytic agents are used, many protocols call for the 
discontinuation of paralytics once the core body-temperature 
target is achieved. The protocol may then allow for paralytic 
resumption if shivering is observed.
Monitoring and supportive therapy
Postarrest patients should be placed on a continuous cardiac 
monitor with monitoring of routine vital signs and oxygen 
saturation. The most commonly encountered arrhythmia 
associated with TH is bradycardia, and a heart rate less than 
40 can be seen frequently, but is rarely a cause for concern 
in the absence of blood-pressure instability. In the event 
of life-threatening dysrhythmia, hemodynamic instability, 
or bleeding, active cooling should be discontinued and 
the patient rewarmed to a higher target.10 A mean arterial 
pressure (MAP) goal of more than 80 mmHg is preferred 
by some because it should theoretically support cerebral 
perfusion, as hypertension in the postresuscitative phase is 
potentially  neuroprotective.21 Norepinephrine,  beginning 
at 0.01 µg/kg/min, can be titrated to whatever MAP goal 
is thought to be best in the individual patient, though 
 practitioners should balance MAP goals and the goal of 
higher  cerebral perfusion with the potential complications 
of increasing cardiac demands.21,42
In addition to the standard neuroprotective strategies, 
such as placing the head of the bed at 30°, lung-protective 
ventilation strategies, standard bedside line and  catheter 
care, and pneumonia-prevention protocols should be 
followed. Skin condition should be checked as frequently 
as every 2–6 hours for potential thermal injury, which can 
be caused by thermal blankets or pads, and for breakdown 
as a consequence of vasoconstriction. Core temperature 
should be monitored hourly and regularly confirmed with 
a secondary temperature-monitoring device when actively 
cooling. Ventilation should be set to maintain CO
2
 partial 
pressure within the reference range (35–45 mmHg) and 
Table 2 Common pharmacologic and bedside adjuncts for tem-
perature management
Initiation of sedation/analgesia
Sedation Propofol (Diprivan): 5 µg/kg per minute intravenously, 
increase by 5–10 µg/kg/min increments every 5 minutes 
until desired sedation is achieved
Dexmedetomidine (Precedex): 1 µg/kg intravenously over 
10 minutes, followed by 0.2–0.7 µg/kg/h continuously
Midazolam (versed): 0.02–0.1 mg/kg/h (1–7 mg/h) 
intravenous infusion
Lorazepam (Ativan): 0.01–0.1 mg/kg/h intravenous 
infusion to maintain desired level of sedation
Analgesia Fentanyl (Sublimaze): 0.7–10 µg/kg/h intravenous 
infusion
Initiation of shiver control
First line Acetaminophen (Tylenol): 650–1,000 mg orally/rectally 
every 4–6 hours
Buspirone (Buspar): 30 mg orally every 8 hours
Meperidine (Demerol): 25–50 mg intravenously every  
4 hours as needed
Application of arm/skin counterwarming via forced-air 
warming unit, hand mitts
Second line Magnesium sulfate: 2–5 g infused over 5 hours
Dexmedetomidine (Precedex): 0.2–0.7 µg/kg/h 
intravenously for mild sedation
Third line Propofol (Diprivan): 50–75 µg/kg/min intravenously to 
deep sedation
vecuronium (Norcuron): 0.1 mg/kg intravenous bolus 
as needed; can be followed by intravenous infusion  
1 µg/kg/min infusion for maintenance 
Goal: bispectral index value 40–60 or one muscle 
twitch out of four in train of four monitoring
Rocuronium (Zemuron): 0.6–1.2 mg/kg intravenous bolus 
as needed, can be followed by a 0.01–0.012 mg/kg/min 
infusion for maintenance 
Goal: bispectral index value 40–60 or one muscle twitch 
out of four in train of four monitoring
Cisatracurium (Nimbex): 0.03 mg/kg intravenous bolus 
as needed; can be followed by a 1–2 µg/kg/min infusion 
for maintenance 
Goal: bispectral index value 40–60 or one muscle 
twitch out of four in train of four monitoring
Initiation of vasopressors
Norepinephrine (Levophed): begin at 0.01 µg/kg/min 
intravenously, titrate to MAP goal
Epinephrine: begin at 2 µg/min intravenously (in adults), 
titrate to MAP goal
Abbreviation: MAP, mean arterial pressure.
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arterial blood gases followed every 6 hours, as metabolic 
end points change with temperature.
Patient hematologic testing, including a complete blood 
count, a basic metabolic panel, troponin level, arterial blood 
gas level, prothrombin time, and partial thromboplastin 
time, should be collected at temperature-management 
initiation (0 hour) and collected every 6–12 hours during 
cooling or as per institutional protocols. An elevated serum 
glucose level is potentially deleterious to the injured brain, 
and glycemic control should be maintained via institutional 
protocol. Hypokalemia, which may be exacerbated by insulin 
administration, commonly occurs as a result of intracellular 
shift during hypothermia. Conversely, potassium exits 
the cells when patients are rewarmed, and hyperkalemia 
may occur, especially if potassium is replaced during the 
rewarming phase. Potassium values less than 3.5 mEq/L 
should be corrected during induction and cooling, but 
potassium administration should be stopped at the final 
2 hours of cooling and once rewarming begins.42,58
Conclusion
TTM remains an integral part of post-cardiac arrest care. Current 
evidence supports either TH at 32°C–34°C or controlled normo-
thermia at 36°C, though individual patient characteristics may 
lead the clinician to favor one target over the other in certain 
cases. In a postarrest patient, continuous temperature monitor-
ing should be initiated as soon as possible, and TTM should be 
started prior to any temperature greater than 36.5°C. No clinical 
benefit has been shown with any particular method of TTM over 
another, although direct normothermia-versus-hypothermia 
comparisons have been limited to advanced techniques. Patients 
undergoing TTM should have continuous cardiac monitoring 
and have electrolyte checks frequently, as abnormalities are 
common in this group of patients. Patients should be sedated, 
and in many cases will require further methods, as discussed, 
to control shivering.
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